Main patient characteristics at diagnosis grouped according to molecular response by deep sequencing
| Characteristic . | Non-MR (n = 80) . | MR (n = 30) . |
|---|---|---|
| Male/female, % | 51/49 | 52/48 |
| Mean age, y (range) | 62 (39-84) | 61 (42-75) |
| Mean β2-microglobulin, mg/L | 4.2 | 4.3 |
| Mean hemoglobin, mg/dL | 11.2 | 11 |
| Mean creatinine, mg/dL | 1 | 1.1 |
| Mean serum calcium, mg/dL | 9.5 | 9.8 |
| Mean albumin, g/dL | 3.7 | 3.4 |
| LDH high, % | 5 | 3 |
| Durie-Samon Stage (I/II/III), % | 10/48/42 | 4/36/60 |
| Durie-Salmon Stage A/B, % | 98/2 | 96/4 |
| IIS I/II/III, % | 49/39/12 | 77/23/0 |
| Bone lesions (nonlesion, minor lesions, major lesions) (%) | 26/42/32 | 33/30/37 |
| Maximum response after front-line therapy*, n | ||
| Complete remission (CR) | 36* | 26* |
| Very good partial remission (VGPR) | 42* | 4* |
| Characteristic . | Non-MR (n = 80) . | MR (n = 30) . |
|---|---|---|
| Male/female, % | 51/49 | 52/48 |
| Mean age, y (range) | 62 (39-84) | 61 (42-75) |
| Mean β2-microglobulin, mg/L | 4.2 | 4.3 |
| Mean hemoglobin, mg/dL | 11.2 | 11 |
| Mean creatinine, mg/dL | 1 | 1.1 |
| Mean serum calcium, mg/dL | 9.5 | 9.8 |
| Mean albumin, g/dL | 3.7 | 3.4 |
| LDH high, % | 5 | 3 |
| Durie-Samon Stage (I/II/III), % | 10/48/42 | 4/36/60 |
| Durie-Salmon Stage A/B, % | 98/2 | 96/4 |
| IIS I/II/III, % | 49/39/12 | 77/23/0 |
| Bone lesions (nonlesion, minor lesions, major lesions) (%) | 26/42/32 | 33/30/37 |
| Maximum response after front-line therapy*, n | ||
| Complete remission (CR) | 36* | 26* |
| Very good partial remission (VGPR) | 42* | 4* |
LDH, lactate dehydrogenase. MR, molecular response.
P(χ2) < .001.